STOCK TITAN

Incyte Genomics (INCY) Stock News, Feb-Apr 2021

INCY NASDAQ

Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.

Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.

Rhea-AI Summary

Eli Lilly and Incyte reported on April 8, 2021, that the COV-BARRIER Phase 3 trial of baricitinib did not meet its primary endpoint of reducing mechanical ventilation or death by Day 28. Baricitinib showed a 2.7% lesser progression risk compared to placebo, which was not statistically significant. However, a significant 38% reduction in all-cause mortality was noted among baricitinib patients. The trial included 1,525 participants across various countries. Lilly plans to publish detailed findings and share them with regulatory authorities for further validation of baricitinib's efficacy in treating COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Eli Lilly and Incyte announced that the FDA has extended the review period for the supplemental New Drug Application for baricitinib, intended for treating adults with moderate to severe atopic dermatitis. The new PDUFA action date is set for early Q3 2021, allowing further review of data analyses submitted by Lilly. Despite this delay, Lilly's financial guidance for 2021 remains unchanged. Baricitinib, an oral JAK inhibitor, is also being researched for other conditions, including COVID-19 and rheumatoid arthritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
Rhea-AI Summary

Incyte's Pemazyre® (pemigatinib) has received approval from the European Commission for treating adults with advanced cholangiocarcinoma exhibiting FGFR2 fusions or rearrangements. This marks the first new treatment for this patient group in over ten years, addressing a critical unmet need. The decision is based on data from the FIGHT-202 study, which showed a 37% overall response rate and an 8-month median duration of response in eligible patients. Incyte aims to ensure rapid patient access across Europe following this significant milestone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.80%
Tags
none
Rhea-AI Summary

Incyte has received approval from Japan's Ministry of Health for Pemazyre® (pemigatinib), targeting patients with unresectable biliary tract cancer (BTC) featuring FGFR2 fusion genes, following chemotherapy failure. This milestone underscores Incyte's commitment to addressing unmet medical needs. The approval stems from the FIGHT-202 study, where Pemazyre showed a 36% overall response rate in patients with FGFR2 fusions. Notably, the Japanese market has designated this as an orphan drug, facilitating quicker access for rare disease treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
none
-
Rhea-AI Summary

Incyte announced results from the Phase 3 DEVENT study assessing ruxolitinib's efficacy in COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). The study did not meet its primary endpoint for overall mortality reduction. However, significant improvements in mortality were noted in the U.S. patient population for both 5mg and 15mg ruxolitinib doses compared to placebo. The safety profile was consistent with existing data. Incyte plans to provide ruxolitinib at no cost to eligible patients through an Expanded Access Program, subject to FDA agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Incyte (Nasdaq: INCY) will present multiple abstracts at the AACR Annual Meeting 2021, showcasing clinical and pre-clinical data from its oncology portfolio. Key highlights include data on INCB106385, an A2A/A2B receptor antagonist, and INCA00186, a CD73 monoclonal antibody. Other presentations will focus on the LIMBER development program, especially a Phase 2 study combining ruxolitinib and parsaclisib for myelofibrosis. All sessions will be available on demand from April 10, 2021, through June 21, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
Rhea-AI Summary

Eli Lilly and Company and Incyte announced positive top-line results from the BRAVE-AA2 Phase 3 trial for baricitinib in treating severe alopecia areata (AA). Both 2-mg and 4-mg doses showed statistically significant scalp hair regrowth at Week 36 compared to placebo. Baricitinib, designated as Breakthrough Therapy by the FDA, aims to address the unmet needs of AA patients, with no current FDA-approved treatments available. The trial involved 546 diverse participants, with no reported severe adverse events. Detailed results will be presented at upcoming conferences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary

Incyte announced the validation of its Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, by the European Medicines Agency (EMA) as a treatment for adult patients with advanced squamous cell anal carcinoma (SCAC) who have progressed on or are intolerant to platinum-based chemotherapy. This validation confirms the submission's completeness for formal review. Retifanlimab has been accepted for Priority Review by the U.S. FDA, marking a significant step towards new treatment options for SCAC patients in Europe, where the incidence is on the rise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary

Incyte announced that the FDA has accepted the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) to treat steroid-refractory chronic graft-versus-host disease (GVHD) in patients aged 12 and older. The FDA's Priority Review designation will expedite the review process to six months. This sNDA is based on the REACH3 study results, where ruxolitinib demonstrated a significantly higher overall response rate (49.7% vs. 25.6%) compared to best available therapy. The target action date for the FDA decision is June 22, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
Rhea-AI Summary

Incyte announced the FDA's acceptance for Priority Review of its NDA for ruxolitinib cream, a selective JAK1/JAK2 inhibitor for atopic dermatitis. This decision is backed by data from the Phase 3 TRuE-AD trials involving over 1,200 participants aged 12 and older. The NDA submission includes a priority review voucher, aiming for a target action date of June 21, 2021. Atopic dermatitis affects over 21 million in the U.S., causing significant skin inflammation and itching. The cream is also under development for vitiligo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none

FAQ

What is the current stock price of Incyte Genomics (INCY)?

Incyte Genomics (INCY) last closed at $119.09.

What is the market cap of Incyte Genomics (INCY)?

The market cap of Incyte Genomics (INCY) is approximately $24.3B.